Targeted Therapy

Data show that rapcabtagene autoleucel (YTB323), a next-generation CAR T-cell therapy, is highly effective in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). In the Phase 1/2 study, the overall response rate reached 86% within three months. All responding patients achieved minimal residual disease (MRD) negativity, meaning no detectable cancer remained. With a […]

Data show that rapcabtagene autoleucel (YTB323), a next-generation CAR T-cell therapy, is highly effective in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). In the Phase 1/2 study, the overall response rate reached 86% within three months. All responding patients achieved minimal residual disease (MRD) negativity, meaning no detectable cancer remained. With a

The Phase 3 TiNivo-2 study tested whether adding nivolumab to tivozanib improves outcomes for patients with metastatic clear cell renal cell carcinoma (ccRCC) who progressed on prior immune checkpoint inhibitors (ICIs). The trial found that combining nivolumab with tivozanib did not improve progression-free survival compared to tivozanib alone. However, tivozanib monotherapy remained highly effective in the

A systematic review shows that using gilteritinib as maintenance therapy after stem cell transplant (HSCT) can significantly improve survival for patients with high-risk, relapsed or refractory FLT3-mutated acute myeloid leukemia (AML). Across eight studies with 134 patients, one-year overall survival ranged from 72% to 100%, and two-year survival remained strong at 56% to 60%. Gilteritinib

Data from a phase 1/2 study presented at the EBMT 52nd Annual Meeting shows that rapcabtagene autoleucel (YTB323), a next-generation CAR T-cell therapy, is highly effective for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). After a median follow-up of 27.7 months, 86% of patients responded to treatment within three months. All responders

A new study reveals that specific proteins called WNT7B and WNT10A drive the aggressive behavior of a subset of pancreatic ductal adenocarcinoma (PDAC), especially the hard-to-treat basal-like subtype. While most PDAC tumors lack common WNT mutations, some cancer cells produce their own WNT ligands, which activate the WNT/β-catenin pathway and push tumors into a more

Doctors are changing how they treat brain metastases in lung cancer, with more patients now starting on targeted drug therapy instead of immediate radiation or surgery. For patients without symptoms who have specific genetic mutations such as EGFR, ALK, ROS1, or RET, doctors are increasingly using modern tyrosine kinase inhibitors (TKIs) first. These drugs can

Researchers at Mayo Clinic have developed a new targeted gene therapy approach for cholangiocarcinoma, a rare and aggressive bile duct cancer. The study, published in JHEP Reports, introduces a precision method that delivers treatment directly to cancer cells while limiting damage to healthy tissue. The system uses small interfering RNA (siRNA) to switch off genes

Interim results from the Phase 1b MAST trial show that azercabtagene zapreleucel (azer-cel), an off-the-shelf CAR T-cell therapy, is highly active in several B-cell cancers. In heavily pretreated patients who had not received prior CAR T therapy, all 4 chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients achieved partial responses, 3 of 5 marginal zone lymphoma

For decades, the standard first-line treatment for Acute Myeloid Leukemia has been the intensive “7+3” chemotherapy regimen, which combines cytarabine with an anthracycline drug. However, experts such as Richard Stone say the dominance of this approach is gradually fading as new targeted and less toxic therapies become available. One major challenger is the combination of